Trastuzumab Deruxtecan Plus Pertuzumab Reduce a Risk of Progression or Death in First-Line Treatment for HER2-positive Advanced or Metastatic Breast Cancer By Ogkologos - November 3, 2025 152 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Breast09 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Liquid Biopsies for Cancer: What to Know and What to Expect November 3, 2022 Thank you! March 22, 2021 Mediterranean Diet Associated with a Higher Probability of Response in Patients... February 28, 2023 Atezolizumab Approved for Initial Treatment of Metastatic Lung Cancer January 7, 2019 Load more HOT NEWS FDA Approves Avelumab for Urothelial Carcinoma Maintenance Treatment Cancer research could revive the UK’s ailing public finances Husband Moved To Tears After Opening Christmas Gift From Wife EMA Recommends Granting a Marketing Authorisation for Pomalidomide Viatris
